MedAvail Holdings, Inc. (MDVLQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MedAvail Holdings, Inc. (MDVLQ) trades at $0.00 with AI Score 50/100 (Grade B). MedAvail Holdings, Inc. Market cap: $161, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MDVLQ: MDVLQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MDVLQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MDVLQ: the 1 perspectives are evenly split.
How is this calculated? →MedAvail Holdings, Inc. (MDVLQ) Healthcare & Pipeline Overview
MedAvail Holdings, Inc. was a technology-enabled retail pharmacy solutions provider, specializing in self-service MedCenters for on-site prescription dispensing with remote pharmacist supervision across the U.S. and Canada. The company is currently undergoing Chapter 7 liquidation, impacting its operational status and market position within the healthcare technology sector.
What Is the Investment Thesis for MDVLQ?
Prior to its Chapter 7 liquidation filing on February 2, 2024, MedAvail Holdings, Inc.'s investment thesis centered on its innovative MedCenter technology, which aimed to disrupt traditional pharmacy models by offering convenient, on-site prescription dispensing with remote pharmacist supervision. The company sought to capitalize on the increasing demand for accessible healthcare solutions and telehealth services, positioning its technology to improve medication adherence and patient experience across clinics, retail, and employer sites. Key value drivers included potential expansion into new geographic markets, partnerships with healthcare providers, and the scalability of its automated dispensing units. However, with the company now undergoing Chapter 7 liquidation, the investment thesis has fundamentally shifted. The focus is no longer on operational growth or market penetration but rather on the orderly disposition of assets to satisfy creditors. Investors holding MDVLQ shares face a high probability of significant or complete loss, as common equity is typically the last to receive distributions, if any, after secured and unsecured creditors are paid.
Based on FMP financials and quantitative analysis
MDVLQ Key Highlights
- Market Capitalization of 161, reflecting the company's current status under Chapter 7 liquidation.
- Profit Margin of -110.5%, indicating substantial net losses relative to revenue prior to its liquidation.
- Gross Margin of 6.0%, suggesting very limited profitability from core sales activities before its bankruptcy.
- Free Cash Flow (FCF) of $-0.03B, highlighting significant cash burn and negative operating cash flow.
- Beta of -106.85, an anomalous figure that typically indicates extreme inverse correlation to the market, but in this context, likely reflects the highly distressed and illiquid nature of the stock post-bankruptcy filing.
Who Are MDVLQ's Competitors?
MDVLQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $114.90M | 50 |
| RNTX Rein Therapeutics, Inc. | $1.01 | +2.37% | $28.38M | 51 |
| TSUSF Tsuruha Holdings Inc. | $17.25 | +0.00% | $4.20B | 49 |
| RADLY Raia Drogasil S.A. | $3.54 | +7.12% | $6.18B | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDVLQ's Key Strengths?
- Innovative MedCenter technology providing self-service prescription dispensing with remote pharmacist supervision.
- Addresses market demand for convenient and accessible healthcare solutions.
- Potential to improve medication adherence by bringing pharmacy services closer to the point of care.
- Operational footprint in both the United States and Canada.
What Are MDVLQ's Weaknesses?
- Currently undergoing Chapter 7 liquidation, indicating severe financial distress and cessation of operations.
- Negative profit margin (-110.5%) and significant free cash flow burn ($-0.03B) prior to bankruptcy.
- Low gross margin (6.0%) suggesting challenges in achieving profitability from core services.
- OTC Other listing (MDVLQ) implies limited liquidity and heightened volatility for its stock.
What Could Drive MDVLQ Stock Higher?
- The Chapter 7 liquidation process, including the sale of company assets and the distribution of proceeds to creditors, will be an ongoing event. Any updates from the bankruptcy court or the appointed trustee regarding asset sales or creditor claims will be relevant.
- Potential final reports or filings from the U.S. Bankruptcy Court for the District of Delaware detailing the conclusion of the liquidation process and the final disposition of MedAvail Holdings, Inc.'s remaining assets and liabilities.
- Official delisting from the OTC markets, which would formally cease trading of MDVLQ shares as the company is dissolved.
What Are the Key Risks for MDVLQ?
- Financial-distress signal — its Altman Z-Score of -15.00 sits in the distress zone (elevated bankruptcy risk).
- The primary risk is the Chapter 7 liquidation, which signifies the cessation of all business operations and the orderly dissolution of the company. Equity holders typically face a complete loss of investment as creditors are prioritized in asset distribution.
- Extremely limited liquidity and high volatility associated with its OTC Other listing, making it difficult to trade shares and potentially leading to significant price fluctuations even with minimal volume.
- Lack of transparency due to the 'Unknown' disclosure status, preventing investors from accessing current financial information or operational updates.
- The possibility of no recovery for common shareholders, as proceeds from asset sales are first used to satisfy secured and unsecured creditors, leaving little to no value for equity holders.
- The risk of permanent delisting from the OTC markets, which would eliminate any remaining trading avenues for MDVLQ shares.
What Are the Growth Opportunities for MDVLQ?
- Prior to its Chapter 7 liquidation, MedAvail Holdings, Inc. aimed to capitalize on the expanding market for convenient, on-site pharmacy services. The company's MedCenter technology was designed to meet the growing demand for immediate prescription access in medical clinics, employer sites, and retail locations. This market segment was driven by consumer preferences for reduced wait times and integrated healthcare experiences, representing a significant opportunity for companies that could efficiently deliver medications at the point of care. The potential market size for such integrated solutions was substantial, encompassing millions of patient visits annually across various healthcare settings.
- Another key growth opportunity MedAvail Holdings, Inc. sought to leverage was the increasing adoption of telehealth and remote healthcare solutions. The MedCenter's audio-visual connection to a live pharmacist aligned directly with the broader trend of virtual care delivery, which gained significant traction due to technological advancements and changing patient expectations. This allowed for pharmacist supervision and consultation without the need for a physical pharmacist on-site, expanding the reach of pharmacy services to underserved areas or locations where a full-scale pharmacy might not be feasible. The telehealth market continues to grow, offering a long-term trend that MedAvail's model was designed to address.
- MedAvail Holdings, Inc. also aimed to penetrate the employer-sponsored healthcare market by offering on-site pharmacy solutions. Companies increasingly seek to provide convenient health services to their employees to improve wellness, reduce absenteeism, and enhance employee satisfaction. The MedCenter could be deployed at large employer campuses, offering immediate access to prescriptions for employees, potentially reducing healthcare costs and improving adherence. This represented a distinct market segment with significant potential for recurring revenue through corporate partnerships, tapping into the multi-billion dollar corporate wellness and benefits market.
- The expansion into the Canadian market represented a geographic growth opportunity for MedAvail Holdings, Inc. The company's presence in both the United States and Canada indicated an intent to scale its technology across different regulatory and healthcare landscapes. While specific market sizes for automated pharmacy solutions in Canada were not provided, the general demand for accessible healthcare and pharmacy services is consistent across developed nations. Successfully navigating the regulatory environment and establishing partnerships in Canada could have provided a diversified revenue stream and expanded the company's total addressable market.
- MedAvail Holdings, Inc. also had the opportunity to enhance medication adherence and patient outcomes through its technology. By making prescriptions readily available at the point of care, the company aimed to reduce barriers to medication access, which is a significant factor in non-adherence. Improved adherence leads to better health outcomes and can reduce overall healthcare costs, creating value for patients, providers, and payers. This focus on value-based care and patient-centric solutions represented a long-term growth driver, as healthcare systems increasingly prioritize outcomes and efficiency, offering a pathway for MedAvail to demonstrate its impact beyond mere dispensing.
What Opportunities Does MDVLQ Have?
- Prior to liquidation, the growing market for automated pharmacy solutions and telehealth services.
- Demand for on-site pharmacy services in clinics, employer sites, and retail locations.
- Potential for partnerships with healthcare systems to enhance patient access and outcomes.
- Expansion into new geographic regions or specialized healthcare segments before its financial collapse.
What Threats Does MDVLQ Face?
- Intense competition from traditional pharmacies, online pharmacies, and other telehealth providers.
- Regulatory hurdles and compliance requirements for pharmacy operations in multiple jurisdictions.
- Capital-intensive nature of hardware deployment and technology development.
- The ongoing Chapter 7 liquidation process, which will result in the dissolution of the company and likely no recovery for equity holders.
What Are MDVLQ's Competitive Advantages?
- Proprietary MedCenter technology integrating self-service dispensing with live remote pharmacist supervision.
- Established presence in both U.S. and Canadian markets for its specific pharmacy kiosk model.
- Ability to offer on-site pharmacy solutions without requiring a full-scale physical pharmacy or on-site pharmacist.
- Potential for strong partnerships with healthcare providers and employers due to convenience and efficiency.
What Does MDVLQ Do?
MedAvail Holdings, Inc. operated as a technology-enabled retail pharmacy technology and services company, focused on developing and commercializing innovative self-service pharmacy, mobile application, and kiosk solutions across the United States and Canada. Headquartered in Phoenix, Arizona, the company's core offering was the MedAvail MedCenter. This advanced pharmacy technology solution was designed to enable on-site prescription dispensing in a variety of settings, including medical clinics, retail store locations, and employer sites, both with and without existing on-site clinics. The MedCenter facilitated direct prescription drug dispensing to patients by establishing an audio-visual connection to a live, licensed pharmacist, ensuring real-time supervision and consultation during the dispensing process. This model aimed to enhance medication access and adherence by bringing pharmacy services closer to the point of care and patient convenience. The company's strategy revolved around leveraging technology to streamline the prescription fulfillment process, reduce wait times, and improve patient engagement with pharmacy services. Prior to its liquidation, MedAvail aimed to address the growing demand for convenient healthcare solutions and automated pharmacy services. However, on February 2, 2024, MedAvail Holdings, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, marking a significant shift from its operational objectives to asset disposition.
What Products and Services Does MDVLQ Offer?
- Develops and commercializes self-service pharmacy technology solutions.
- Offers the MedAvail MedCenter, a kiosk-based system for prescription dispensing.
- Enables on-site pharmacy services in medical clinics, retail stores, and employer sites.
- Establishes an audio-visual connection for real-time supervision by a live pharmacist.
- Facilitates direct prescription drug dispensing to patients.
- Aims to improve medication access and adherence through technology.
- Operates in the United States and Canada.
- Filed for Chapter 7 liquidation on February 2, 2024.
How Does MDVLQ Make Money?
- Prior to liquidation, generated revenue through the sale and deployment of MedAvail MedCenter units.
- Likely earned recurring revenue from software licenses, maintenance, and support services for its technology.
- Potentially engaged in partnerships with healthcare providers, clinics, and employers for integrated pharmacy solutions.
- Focused on a technology-enabled services model, combining hardware with software and remote pharmacist support.
What Industry Does MDVLQ Operate In?
MedAvail Holdings, Inc. operated within the dynamic healthcare technology and medical pharmaceuticals industry, a sector characterized by ongoing innovation in patient care delivery and medication access. The company positioned itself within the growing segment of pharmacy automation and telehealth services, aiming to address market trends such as the demand for greater convenience, reduced wait times, and improved medication adherence. Before its liquidation, MedAvail's MedCenter technology competed by offering a unique hybrid model of self-service dispensing coupled with live remote pharmacist interaction, differentiating it from traditional brick-and-mortar pharmacies and pure online pharmacy models. The broader industry landscape includes large retail pharmacy chains, pharmacy benefit managers (PBMs), and emerging telehealth platforms. MedAvail sought to carve out a niche by integrating pharmacy services directly into healthcare points of care, a strategy aligned with the broader industry push towards decentralized and patient-centric healthcare solutions.
Who Are MDVLQ's Key Customers?
- Medical clinics seeking on-site pharmacy capabilities.
- Retail store locations looking to offer convenient prescription services.
- Employer sites aiming to provide accessible healthcare benefits to employees.
- Patients requiring immediate and convenient access to prescription medications.
- Healthcare systems and providers interested in enhancing medication adherence and patient experience.
Company Profile
MedAvail Holdings, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Phoenix, US. The company is led by CEO Emilia Keric. MDVLQ has traded publicly since 2020.
MedAvail Holdings, Inc. (MDVLQ) Valuation Context
Valued at 161, MDVLQ is classified as a micro-cap stock. Relative to its peer group, MDVLQ's quantitative score of 50/100 is below the peer average of 60/100.
F-Score 4/9Financial Health
MedAvail Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -15.00 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project MedAvail Holdings, Inc. revenue of about $43.2M for fiscal 2026, with EPS near $-3.50.
MDVLQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MedAvail's future prospects, indicating that key executives believe in the company's recovery potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to pharmacy services as a game changer in the healthcare sector.
- Recent partnerships and collaborations have sparked interest, positioning MedAvail as a contender in the evolving telehealth landscape.
- The growing demand for convenient healthcare solutions aligns with MedAvail's business model, which may attract more users and boost market presence.
Bear Case
- Concerns about the company's financial stability persist, as some investors remain wary of its ability to navigate current market challenges effectively.
- Negative community sentiment has emerged, with discussions focusing on the lack of clear profitability timelines, leading to skepticism about long-term viability.
- Recent regulatory hurdles have raised questions about MedAvail's operational capabilities, potentially impacting its growth trajectory in a competitive market.
- Some analysts express doubts about the scalability of MedAvail's services, fearing that the business model may not be sustainable in the long run.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MDVLQ Latest News
No recent news available for MDVLQ.
MDVLQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDVLQ.
Price Targets
Wall Street price target analysis for MDVLQ.
MDVLQ MoonshotScore
What does this score mean?
The MoonshotScore rates MDVLQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Emilia Keric
Chief Executive Officer
Emilia Keric served as a key leader at MedAvail Holdings, Inc., overseeing the company's operations and strategic direction. While specific details regarding her full career history and educational background are not provided in the source data, her role involved managing a workforce of 279 employees. This indicates significant experience in organizational leadership and operational management within a technology-focused healthcare environment, particularly in scaling and deploying complex pharmacy solutions across multiple markets.
Track Record: Under Emilia Keric's leadership, MedAvail Holdings, Inc. focused on developing and commercializing its self-service pharmacy and kiosk solutions, expanding its footprint in the United States and Canada. Her tenure was marked by efforts to position the MedCenter as an innovative solution for on-site prescription dispensing. However, the company ultimately filed for Chapter 7 liquidation on February 2, 2024, indicating that despite these efforts, the business model faced insurmountable financial challenges.
MDVLQ OTC Market Information
MedAvail Holdings, Inc. (MDVLQ) trades on the OTC Other tier of the OTC markets. This tier is distinct from major exchanges like the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, market capitalization, and corporate governance. OTC Other, often referred to as the 'Pink No Information' tier, signifies that the company does not provide current or publicly available information to OTC Markets Group. This contrasts sharply with OTCQX and OTCQB, which have higher disclosure standards, or even Pink Current Information, which requires some level of public disclosure. Companies on OTC Other typically have limited transparency and are often distressed or defunct.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extreme lack of transparency due to 'Unknown' disclosure status, making fundamental analysis nearly impossible.
- Significantly limited liquidity and wide bid-ask spreads, leading to high price volatility and difficulty in executing trades.
- High susceptibility to fraud and manipulation due to minimal regulatory oversight compared to major exchanges.
- The company's Chapter 7 liquidation filing indicates a cessation of operations and likely no recovery for equity holders.
- Absence of analyst coverage and institutional interest, contributing to poor market efficiency.
- Verify the company's current legal and financial status, specifically the Chapter 7 liquidation proceedings.
- Scrutinize any available bankruptcy court filings for details on asset disposition and creditor priority.
- Assess the likelihood of any recovery for equity holders, which is typically very low in Chapter 7 liquidations.
- Understand the implications of the 'OTC Other' tier, including disclosure levels and trading risks.
- Research any news or official statements from the bankruptcy trustee regarding the liquidation process.
- Be aware of the extremely high risk of total loss of investment in such a distressed security.
- Consult with legal and financial advisors experienced in bankruptcy proceedings before any action.
- Regular and timely financial reporting (not applicable for MDVLQ due to 'Unknown' disclosure).
- Listing on higher OTC tiers (e.g., OTCQX or OTCQB) or major exchanges (not applicable for MDVLQ).
- Transparent communication from management regarding business operations and financial performance (not applicable for MDVLQ).
- Clear business operations and verifiable assets (assets are now subject to liquidation proceedings).
- Independent auditor reports and robust corporate governance (unlikely for an OTC Other company in liquidation).
Common Questions About MDVLQ (Healthcare)
What does MedAvail Holdings, Inc. do?
MedAvail Holdings, Inc. was a technology-enabled retail pharmacy technology and services company. Its core offering was the MedAvail MedCenter, a self-service kiosk solution that enabled on-site prescription dispensing in various locations such as medical clinics, retail stores, and employer sites across the United States and Canada. This system established an audio-visual connection to a live pharmacist, allowing for real-time supervision and direct prescription delivery to patients. The company aimed to enhance medication access and adherence through this innovative, convenient model. However, it is important to note that MedAvail Holdings, Inc. filed for Chapter 7 liquidation on February 2, 2024, meaning its operational activities have ceased.
What are the main risks for MDVLQ?
The primary and most significant risk for MDVLQ is its ongoing Chapter 7 liquidation, which means the company is being dissolved, and its assets are being sold to pay off creditors. This process typically results in common shareholders receiving little to no recovery on their investment. Additional risks stem from its listing on the OTC Other tier, which is characterized by an 'Unknown' disclosure status, leading to extreme lack of transparency regarding financial and operational information. This tier also implies severely limited liquidity, wide bid-ask spreads, and high price volatility, making it very difficult to buy or sell shares. The combination of liquidation and OTC status presents an exceptionally high risk of total capital loss for investors.
What is the current status of MedAvail Holdings, Inc. following its Chapter 7 filing?
As of February 2, 2024, MedAvail Holdings, Inc. along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. This means the company has ceased its business operations and is undergoing a formal process to sell off its assets to repay its debts. A bankruptcy trustee has been appointed to manage this process. For investors, a Chapter 7 liquidation typically results in the cancellation of common stock and little to no distribution to equity holders, as creditors are prioritized in the distribution of any remaining assets. The company is effectively being dissolved.
How did MedAvail Holdings, Inc.'s technology aim to improve healthcare access?
MedAvail Holdings, Inc.'s MedCenter technology aimed to significantly improve healthcare access by bringing pharmacy services directly to the point of care or patient convenience locations. By deploying self-service kiosks in medical clinics, retail stores, and employer sites, the company sought to reduce the need for patients to travel to traditional pharmacies. The integrated audio-visual connection to a live pharmacist ensured professional supervision and consultation, maintaining safety and quality standards while offering immediate prescription dispensing. This model was designed to overcome geographical barriers, reduce wait times, and enhance medication adherence by making it easier and faster for patients to obtain their prescribed drugs, thereby streamlining the patient journey within the healthcare ecosystem.
What are the key factors to evaluate for MDVLQ?
MedAvail Holdings, Inc. (MDVLQ) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does MDVLQ data refresh on this page?
MDVLQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MDVLQ's recent stock price performance?
MedAvail Holdings, Inc. (MDVLQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative MedCenter technology providing self-service prescription dispensing with remote pharmacist supervision. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDVLQ overvalued or undervalued right now?
Valuing MedAvail Holdings, Inc. (MDVLQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word counts for 'growthOpportunities' and 'investmentThesis' were challenging due to the Chapter 7 liquidation status. Content was framed to describe the company's past business model and intended opportunities, while clearly stating the current liquidation context.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per instructions.
- CEO title was inferred as 'Chief Executive Officer' as only 'managing 279 employees' was provided for Emilia Keric.